Pyxis Oncology, Inc.PYXS

Pyxis Oncology is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) and immunotherapies for difficult-to-treat cancers. Its lead candidates target solid tumors, including a Phase 2 ADC for recurrent glioblastoma and a preclinical ADC for multiple solid tumors. Investors track Pyxis for its focused pipeline in the high-risk, high-reward ADC space, though the company has no approved products and relies on funding from partnerships and equity raises.